Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, Amelio J (2017) Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol 115:67–80

Article  PubMed  Google Scholar 

Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomark Prev 26(6):809–815

Article  Google Scholar 

Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61–66

Article  CAS  PubMed  PubMed Central  Google Scholar 

Plunkett TA, Smith P, Rubens RD (2000) Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 36(4):476–482

Article  CAS  PubMed  Google Scholar 

Hofbauer LC, Bozec A, Rauner M, Jakob F, Perner S, Pantel K (2021) Novel approaches to target the microenvironment of bone metastasis. Nat Rev Clin Oncol 18(8):488–505

Article  PubMed  Google Scholar 

Cook GJ, Azad GK, Goh V (2016) Imaging bone metastases in breast cancer: staging and response assessment. J Nucl Med 57(Suppl 1):27S-33S

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

Article  CAS  PubMed  Google Scholar 

Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM et al (2009) Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10(6):606–614

Article  PubMed  Google Scholar 

Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall’Olio FG, Madison RW, Fine AD, Oxnard GR, Graf RP et al (2023) Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol 34(1):111–120

Article  CAS  PubMed  Google Scholar 

FoundationOne Liquid CDx - P190032 [https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-liquid-cdx-f1-liquid-cdx-p190032s005#:~:text=The%20FoundationOne%20Liquid%20CDx%20assay,from%20specific%20FDA%2Dapproved%20treatments.]

Guardant360 CDx – P200010/S001 [https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S001C.pdf]

Christian R, Philip M, Giorgio VS, Charu A, Maria EA, Fabrice B, Trever B, Maximilian D, Caroline D, Rafal D et al (2021) Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol 16(10):1647–1662

Article  Google Scholar 

Keller L, Belloum Y, Wikman H, Pantel K (2021) Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer 124(2):345–358

Article  PubMed  Google Scholar 

Miron B, Li G, Quintanilha JCF, Clark A, Scott T, Ross JS, Oxnard GR, Pasquina LW, Graf RP, Gupta S (2024) Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer. ESMO Real World Data and Digital Oncology

Pathak P, Li G, Quintanilha J, Keller RB, Pasquina L, Thierauf J, Graf R, Parikh AR, Pishvaian MJ (2024) Relationship of tumor fraction in circulating tumor DNA (ctDNA) with prognosis in patients with metastatic pancreatic cancer. J Clin Oncol 42(3_suppl):621–621

Article  Google Scholar 

Antonarakis ES, Tierno M, Fisher V, Tukachinsky H, Alexander S, Hamdani O, Hiemenz MC, Huang RSP, Oxnard GR, Graf RP (2022) Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer. Prostate 82(7):867–875

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayle A, Belcaid L, Cousin S, Trin K, Alame M, Rouleau E, Soubeyran I, Lacroix L, Blouin L, Vasseur D et al (2024) Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials. NPJ Precis Oncol 8(1):227

Article  PubMed  PubMed Central  Google Scholar 

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM et al (2019) Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA 321(14):1391–1399

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31(11):1023–1031

Article  CAS  PubMed  PubMed Central  Google Scholar 

He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE et al (2016) Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood 127(24):3004–3014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, Meng W, Dewal N, Milbury C, Clark T et al (2020) Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15(9):e0237802

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP et al (2021) Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin Cancer Res 27(11):3094–3105

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Fendler B, Yang L, Madison R, Decker B, Gjoerup O, McGregor K, Aiyer A, Hughes J, Hegde P et al (2021) Abstract 2231: utility of plasma tumor fraction (TF) to inform sensitivity of FoundationOne Liquid CDx (F1LCDx). Cancer Res 81(13_Supplement):2231–2231

Article  Google Scholar 

Rolfo CD, Madison R, Pasquina LW, Brown DW, Huang Y, Hughes JD, Oxnard GR, Husain H (2023) Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC). J Clin Oncol 41(16_suppl):9076–9076

Article  Google Scholar 

Chiang AC, Madison RW, Huang Y, Fine A, Jin DX, Oxnard GR, Hughes J, Assaf ZJ, Cao Y, Antic V et al (2024) Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC). Cancer Res 84(6_Supplement):971–971

Article  Google Scholar 

McGough SF, Incerti D, Lyalina S, Copping R, Narasimhan B, Tibshirani R (2021) Penalized regression for left-truncated and right-censored survival data. Stat Med 40(25):5487–5500

Article  PubMed  PubMed Central  Google Scholar 

Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N et al (2022) Implications of selection bias due to delayed study entry in clinical genomic studies. JAMA Oncol 8(2):287–291

Article  PubMed  PubMed Central  Google Scholar 

Zhang Q, Gossai A, Monroe S, Nussbaum NC, Parrinello CM (2021) Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States. Health Serv Res 56(6):1281–1287

Article  PubMed  PubMed Central  Google Scholar 

Quintanilha JCF, Graf RP, Fisher VA, Oxnard GR, Ellis H, Panarelli N, Lin DI, Li G, Huang RSP, Ross JS et al (2023) Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy in patients with metastatic colorectal cancer with measures of microsatellite instability, mismatch repair, or tumor mutational burden. JAMA Netw Open 6(1):e2252244–e2252244

Article  PubMed  PubMed Central  Google Scholar 

Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB et al (2022) Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer. JAMA Netw Open 5(3):e225394–e225394

Article  PubMed  PubMed Central  Google Scholar 

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223–238

Article  CAS  PubMed  Google Scholar 

Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J et al (2018) Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol 36(6):543–553

Article  CAS